drugset / Trial / NCT04263909

The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients

NCT04263909

Phase 4 Completed 199 enrolled Brigham and Women's Hospital
NaSingle-groupOpen-labelTreatment

Summary

In this study the investigators plan to examine the perioperative use of sufentanil sublingual (SL) in the analgesic regimen for spine surgery, one of the most common surgeries performed in the US. Patients undergoing spinal fusion surgery often experience severe pain during the first three postoperative days. Currently, no data are available for this patient population which routinely experiences moderate to severe acute pain. The investigators will analyze whether sufentanil SL is associated with lower opioid consumption in the post anesthesia care unit and pain scores.

Timeline

Start
2020-12-01
Primary completion
2022-04-01
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 30 ug Other